CMV ICP22 Antibodies

Santa Cruz Biotechnology offers a broad range of CMV ICP22 monoclonal antibodies for research focused on understanding ICP22 protein function in cytomegalovirus (CMV) infection. CMV ICP22 monoclonal antibodies are suitable for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CMV ICP22 protein functions as a key component in the viral replication cycle by modulating host cell responses and enhancing viral gene expression. Research involving CMV ICP22 is vital for developing therapeutic strategies against CMV-related diseases, which pose significant risks to immunocompromised patients. Investigating CMV ICP22 provides valuable insights into viral pathogenesis and host-virus interactions. Researchers can utilize CMV ICP22 monoclonal antibodies to conduct detailed analyses of protein localization, expression patterns, and molecular interactions. Advanced visualization techniques with CMV ICP22 monoclonal antibodies enable precise tracking of protein dynamics during viral infection. Understanding CMV ICP22 behavior throughout the infection cycle helps identify potential therapeutic targets. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific knowledge of viral mechanisms and potential treatment strategies.